• Established in 1997 in Beijing, the first global  pharmaceutical R&D centre in China
  • Full capabilities in drug discovery, from early-stage target identification to preclinical studies
  • A centre of excellence in protein engineering, pharmacology and target discovery
  • World class research facilities including rodent and dog facilities that meet European standards
  • A host of high calibre talents in drug discovery, constantly pushing our innovation boundaries

For years, we have successfully leveraged our core capabilities in engineering, formulating, developing and delivering peptide- and protein-based treatments for those living with serious chronic diseases. To ensure future success of our discovery processes, we continuously strengthen our capabilities and invest in emerging and cutting-edge technologies. 

Find more here...



INNOVO®, Novo Nordisk's open innovation platform in China, invites you to innovate with us. Aiming to be a preferred partner to accelerate innovation, we are open to research collaborations with dynamic forces in China.

Find collaboration opportunities here...



We enable and accelerate early drug discovery programs with world-class protein and peptide technologies for expression, production, characterisation, display-based lead selection, unbiased phenotypic screening and ligand / receptor deorphanisatio.

We are competent in the design, screening, in vitro and/or in vivo delivery of RNAi molecules (siRNA, ASO, shRNA, etc) for tissue-selective and efficient target intervention and PK/PD evaluation.

At the heart of our approach to early target discovery is the adoption of a battery of highly human relevant in vitro models that faithfully capture the underlying disease mechanisms. Complementing the existing cell lines and animal cells, we have developed many modern world assays with the use of primary human cells, iPSCderived cells, organoids and organ-on -a-chip in which multiplexed molecular and phenotypic consequences are measured.

We have a collection of acute and chronic rodent models of Diabetes, Obesity, Heart Failure, Atherosclerosis, NASH, etc, for mode of actions and/or efficacy evaluation. A wide range of readouts can be measured with in vivo studies, including body weight, food intake, body composition, lipid profile, cytokine panels, tissue ISH and IHC, cardiac functions, etc.

We established LC/MS based and ligandbinding based analysis platforms for plasma and tissue biomarker measurement and PK analysis, and Cobas system for plasma biochemical parameter evaluation. We are also setting up new technologies, such as stemloop qPCR and hybridisation ELISA, for the measurement of oligonucleotides.

Your Career Guide